| 张 璐,常彩莲,王 武,王思雯,孙丽娜,李 茜,温元善.沙库巴曲缬沙坦钠片对高原地区慢性心力衰竭患者神经内分泌激素和心功能的影响[J].,2021,(12):2350-2353 |
| 沙库巴曲缬沙坦钠片对高原地区慢性心力衰竭患者神经内分泌激素和心功能的影响 |
| Effect of Sacubatrovalsartan Sodium Tablet on Neuroendocrine Hormones and Cardiac Function in Patients with Chronic Heart Failure at High Altitude |
| 投稿时间：2020-09-23 修订日期：2020-10-18 |
| DOI：10.13241/j.cnki.pmb.2021.12.033 |
| 中文关键词: 沙库巴曲缬沙坦钠片 高原地区 慢性心力衰竭 疗效 神经内分泌激素 心功能 |
| 英文关键词: Sacubatrovalsartan sodium tablets High altitude Chronic heart failure Efficacy Neuroendocrine hormone Heart function |
| 基金项目:青海省科技计划项目(2014-ZJ-741) |
|
| 摘要点击次数: 738 |
| 全文下载次数: 558 |
| 中文摘要: |
| 摘要 目的：探讨沙库巴曲缬沙坦钠片治疗高原地区慢性心力衰竭（CHF）患者的疗效及对神经内分泌激素和心功能的影响。方法：选取2017年3月~2019年6月期间我院接收的CHF患者109例。根据随机数字表法将患者随机分为对照组（n=54）和研究组（n=55），对照组患者予以缬沙坦治疗，研究组患者则予以沙库巴曲缬沙坦钠片治疗，比较两组患者疗效、神经内分泌激素指标[去甲肾上腺素（NA）、醛固酮（ALD）、血管紧张素Ⅱ（AngⅡ）]和心功能指标[超敏心肌肌钙蛋白T（hs-cTnT）、N-末端脑钠肽前体（NT-proBNP）、左房内径（LAD）、左室舒张末期内径（LVEDD）以及左室射血分数（LVEF）]。记录两组患者心血管不良事件发生情况。结果：研究组患者治疗12周后总有效率为90.91%（50/55），显著高于对照组患者的75.93%（41/54）（P<0.05）。两组治疗12周后ALD、NA、AngⅡ均下降，且研究组低于对照组（P<0.05）。两组治疗12周后hs-cTnT、NT-proBNP、LVEDD、LAD均下降，且研究组低于对照组（P<0.05）；LVEF升高，且研究组高于对照组（P<0.05）。两组心血管不良事件发生率对比无差异（P>0.05）。结论：沙库巴曲缬沙坦钠片治疗高原地区CHF患者，疗效显著，可有效改善神经内分泌激素水平和心功能，且不增加心血管不良事件发生率，临床应用价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of sacubatrovalsartan sodium in the treatment of chronic heart failure (CHF) at high altitude and its influence on neuroendocrine hormone and cardiac function. Methods: From March 2017 to June 2019, 109 patients with CHF who were admitted to our hospital were selected. Patients were randomly divided into control group (n=54) and study group (n=55) according to the method of random number table. Patients in the control group were treated with valsartan, while patients in the study group were treated with sodium sakubatrovalsartan. The curative effect, neuroendocrine hormone indexes [(norepinephrine (NA), aldosterone (ALD), angiotensin Ⅱ (Ang Ⅱ)] and cardiac function indexes [high sensitivity cardiac troponin T (hs-cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP), left atrial diameter (LAD), left ventricular end diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF)] were compared between the two groups. The incidence of cardiovascular adverse events of the two groups was recorded. Results: The total effective rate of the study group was 90.91%(50/55) at 12 weeks after treatment, which was significantly higher than 75.93% (41/54) of the control group (P<0.05). 12 weeks after treatment, ALD, NA, AngⅡ decreased in the two groups, and those of the study group were lower than those of the control group(P<0.05). 12 weeks after treatment, hs-cTnT, NT-proBNP, LVEDD and LAD were all decreased of the two groups, and those of the study group were lower than those of the control group(P<0.05). The LVEF increased, and that of the study group was higher than that of the control group(P<0.05). There was no difference in the incidence of cardiovascular adverse events between the two groups(P>0.05). Conclusion: Sacubatrovalsartan sodium is effective in the treatment of CHF at high altitude. It can effectively improve the neuroendocrine hormone and cardiac function without increasing the incidence of adverse events. It has a high clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
